Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Position Lifted by California Public Employees Retirement System

California Public Employees Retirement System lifted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 42.5% in the 4th quarter, HoldingsChannel reports. The firm owned 278,294 shares of the specialty pharmaceutical company’s stock after purchasing an additional 83,065 shares during the quarter. California Public Employees Retirement System’s holdings in Jazz Pharmaceuticals were worth $34,230,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. International Assets Investment Management LLC bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $7,201,000. Desjardins Global Asset Management Inc. bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at about $1,943,000. DekaBank Deutsche Girozentrale boosted its stake in Jazz Pharmaceuticals by 94.2% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 91,540 shares of the specialty pharmaceutical company’s stock valued at $11,210,000 after buying an additional 44,414 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in Jazz Pharmaceuticals by 558.6% during the third quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock valued at $41,780,000 after buying an additional 273,764 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in Jazz Pharmaceuticals by 40.8% during the third quarter. AQR Capital Management LLC now owns 179,111 shares of the specialty pharmaceutical company’s stock valued at $23,184,000 after buying an additional 51,871 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CFO Philip L. Johnson purchased 12,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the purchase, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The disclosure for this sale can be found here. Company insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Stock Up 1.9 %

Shares of Jazz Pharmaceuticals stock opened at $109.46 on Friday. The stock has a 50-day moving average price of $118.25 and a 200 day moving average price of $121.81. The company has a market cap of $6.90 billion, a P/E ratio of 17.89, a P/E/G ratio of 1.48 and a beta of 0.59. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37. Jazz Pharmaceuticals plc has a 1 year low of $106.61 and a 1 year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. As a group, analysts expect that Jazz Pharmaceuticals plc will post 16.24 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on JAZZ shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $180.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $195.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, February 29th. Stifel Nicolaus raised their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Piper Sandler upped their target price on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. Finally, Robert W. Baird started coverage on Jazz Pharmaceuticals in a report on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 target price for the company. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $195.08.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.